| NCT Number | Conditions | Interventions | Sponsor/Collaborators | Phases | Start Date | Last Updated |
| NCT02530437 | Esophageal Cancer | Drug: Taladegib|Drug: Paclitaxel|Drug: Carboplatin|Radiation: Radiation Therapy|Procedure: Endoscopy | M.D. Anderson Cancer Center|National Cancer Institute (NCI)|Eli Lilly and Company | Phase 1|Phase 2 | 2017-03-07 | 2017-03-07 |
| NCT01919398 | Neoplasm Metastasis | Drug: LY2940680 | Eli Lilly and Company | Phase 1 | 2013-08-01 | 2016-08-26 |
| NCT01697514 | Medulloblastoma, Childhood|Rhabdomyosarcoma | Drug: LY2940680|Drug: LY2940680 | Eli Lilly and Company | Phase 1 | 2013-07-01 | 2013-08-26 |
| NCT01746745 | Healthy Volunteers | Drug: [C14]-LY2940680 | Eli Lilly and Company | Phase 1 | 2013-01-01 | 2013-03-14 |
| NCT01722292 | Small Cell Lung Carcinoma | Drug: LY2940680|Drug: Carboplatin|Drug: Etoposide|Drug: Placebo | Eli Lilly and Company | Phase 1|Phase 2 | 2013-01-01 | 2015-09-30 |
| NCT01681186 | Healthy Volunteers | Drug: LY2940680 Capsule(s) (Reference)|Drug: LY2940680 Tablet (Test)|Drug: Lanzoprazole|Drug: Placebo Capsule(s) | Eli Lilly and Company | Phase 1 | 2012-09-01 | 2013-01-11 |
| NCT01226485 | Advanced Cancer | Drug: RXDX-109 | Ignyta, Inc. | Phase 1 | 2010-09-01 | 2016-11-08 |
| NCT02784795 | Solid Tumor|Breast Cancer|Colon Cancer|Cholangiocarcinoma|Soft Tissue Sarcoma | Drug: LY3039478|Drug: Taladegib|Drug: Abemaciclib|Drug: Cisplatin|Drug: Gemcitabine|Drug: Carboplatin|Drug: LY3023414 | Eli Lilly and Company | Phase 1 | 2016-11-01 | 2017-03-27 |
